Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 9/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 9/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599491 | 1.00 | KEAP1 (1.00) | KEAP1NFE2L2MEN1KMT2AKDM4E | |
| SCHEMBL17599442 | 1.00 | KEAP1 (1.00) | KEAP1NFE2L2MEN1KMT2AKDM4E | |
| SCHEMBL17599452 | 1.00 | KEAP1 (1.00) | KEAP1NFE2L2MEN1KMT2AKDM4E | |
| SCHEMBL24811433 | 0.94 | KEAP1 (0.89) | KEAP1NFE2L2MEN1KMT2AKDM4E | |
| SCHEMBL17599417 | 0.94 | KEAP1 (0.89) | KEAP1NFE2L2MEN1KMT2AKDM4E | |
| SCHEMBL17599488 | 0.94 | KEAP1 (0.89) | KEAP1NFE2L2MEN1KMT2AKDM4E | |
| SCHEMBL17599434 | 0.94 | KEAP1 (0.89) | KEAP1NFE2L2MEN1KMT2AKDM4E | |
| SCHEMBL24812743 | 0.93 | KEAP1 (0.87) | KEAP1NFE2L2NOTUM | |
| SCHEMBL24811431 | 0.92 | KEAP1 (0.85) | KEAP1NFE2L2MEN1KMT2AKDM4E | |
| SCHEMBL25802809 | 0.92 | KEAP1 (0.85) | KEAP1NFE2L2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024199144-A1 | NOVEL REAGENT FOR MITIGATING LNP TOXICITY | SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | WO | claimed |
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250251402-A1 | METHODS OF DETECTING MOLECULAR AGGREGATES USING IMAGE CORRELATION SPECTROSCOPY (ICS) | THE GENERAL HOSPITAL CORPORATION | 2025-08-07 | — | — | US | disclosed |
| WO-2025096856-A1 | COVALENT CEREBLON LIGANDS | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025024320-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | REGENCOR, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-119325475-A | Bicyclic substituted glutarimide cereblon binders | C4医药公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024199144-A1 | NOVEL REAGENT FOR MITIGATING LNP TOXICITY | SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | WO | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023196621-A1 | METHODS OF DETECTING MOLECULAR AGGREGATES USING IMAGE CORRELATION SPECTROSCOPY (ICS) | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4146226-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-115803059-A | Methods of treating covi-19 using bardoxolone methyl or analogs thereof | 里亚塔医药控股有限责任公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | KEAP1 197/4885NFE2L2 1608/4885MEN1 1742/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | KEAP1 584/4885NFE2L2 2859/4885MEN1 728/4885 |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | KEAP1 197/4885NFE2L2 1608/4885MEN1 1742/4885 |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | CYP17A1, HSD11B2, HSD11B1 | KEAP1 207/4885NFE2L2 553/4885MEN1 864/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | KEAP1 197/4885NFE2L2 1608/4885MEN1 1742/4885 |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | CRBN, STUB1, CUL1 | KEAP1 197/4885NFE2L2 1608/4885MEN1 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.